Global Antiretroviral Market

combination of multiple antiretroviral drugs. They tend to reduce the efficacy of the virus, thus maintaining a comparatively high defense system. If a mutation develops a resistance to one of the drugs, the other drugs tend to suppress that mutation.

End User/Technology

Entry inhibitors (or fusion inhibitors) interfere with binding, fusion, and entry of HIV-1 to the host cell by blocking one of the several targets. Integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) inhibit the viral enzyme integrase, which is responsible for the integration of viral DNA into the DNA of the infected cell.Raltegravir,elvitegravir, and dolutegravir are examples of this drug.Protease inhibitors block the viral protease enzyme necessary to produce mature virions upon budding from the host membrane. Virus particles produced in the presence of protease inhibitors are defective and mostly non-infectious

Market Dynamics

ART(Anti-Retroviral Therapy) is facing numerous challenges in developing countries like a fixed combination of doses, increasing guidelines laid down by the healthcare department which are to be strictly adhered to, more number of infected people and increasing prices of drugs. Purchase volume of ARV increased 15 times from 2006 to 2008.More and more countries are moving towards the new regimens most of which have patents as opposed to the older regimens which were not patented. This has aggravated the problem, particularly in India, Thailand, and Brazil. Although WHO recommends FDCs (Fixed Dosage Combination), very few of these are available in the market. Strong R&D is one of the most important criteria driving the supply. But the high cost in R&D, the risk of failure and government laws are hindrances to it.

Market driver

--> Rising awareness of retroviral infection

Market challenge

--> High cost of antiretroviral drugs

Market opportunities

--> Significant pipeline

Market segmentation

Based on the inhibition of phase of retrovirus life-cycle:

--> Entry Inhibitors

--> Nucleotide/Nucleoside Reverse Transcriptase Inhibitors

--> Non-Nucleotide Reverse Transcriptase Inhibitors

--> Integrase Inhibitors

--> Protease Inhibitors

Based on geography

--> Asia-Pacific

--> Europe and Middle-East

--> North America

--> Latin America

Regional/Geographic Analysis

. In recent years, Pakistan has witnessed a concentrated epidemic of HIV.Majority of sequences were of subtype A, while the rest of the sequences were of subtypes B (9.5%), K (2%), D (2%) and AE (1%). The trees had similarity with India, Afghanistan as well as some African nations. Although HIV-1 subtype B is predominant in the United States, factors such as global travel, immigration, and military deployment have the potential to increase the proportion of non-subtype B infections. Limited data are available on the prevalence and distribution of non-B HIV-1 strains in the United States. Kenya was the first country to use Dolutegravir, followed by Nigeria and Uganda.

Major companies

--> Tibotec Pharmaceuticals

--> Cipla

--> Gilead Sciences

Report Contents:

> Market segments

> Market Drivers, Restraints and Opportunities

> Market Size & Forecast 2016 to 2022

> Supply & Demand Value Chain

> Market - Current Trends

> Competition & Major Companies

> Technology and R&D Status

> Porters Five Force Analysis

> Strategic and Critical Success Factor Analysis of Key Players

Regional Analysis:

> North America

>> US and Canada

> Latin America

>> Mexico, Brazil, Argentina and Rest of Latin America

> Western Europe

>> EU5 (Germany, France, Italy, Spain, U.K.)

>> Nordic Countries (Denmark, Finland, Norway, and Sweden)

>> Benelux (Belgium, The Netherlands, and Luxembourg)

>> Rest of Western Europe

> Eastern Europe

>> Russia

>> Poland

>> Rest of Eastern Europe

> Asia Pacific

>> China

>> India

>> Japan

>> Australia and New Zealand

>> Rest of Asia Pacific

> Middle East and Africa

>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)

>> South Africa

>> North Africa

>> Rest of Middle East and Africa

This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides details on market segmentation which is derived from several product mapping exercises, macroeconomic parameters and other qualitative and quantitative insights. The impact of all such factors is delivered across multiple market segments and geographies.

Report Highlights:

> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)

> Consumer and Pricing Analysis

> Market dynamics of the industry

> Market Segmentation

> Estimated Market Sizing in terms of volume and value

> Recent trends in Market and impact

> Research Status and Technology Overview

> Extensive Industry Structure Coverage